

ASX Release

FIRST RESPONDER SCANNER UNVEILED

EMVision Medical Devices Limited (ASX:EMV) (“EMVision” or the “Company”) is pleased to announce that the fabrication of the Company’s First Responder (Gen 2) Proof of Concept device has been completed.

The First Responder device, pictured below, represents an opportunity to fundamentally transform stroke and traumatic brain injury outcomes for all patients, regardless of their location, by delivering sophisticated neurodiagnostic technology directly to the point of care. The Proof-of-Concept device leverages the principles and mode of operation of EMVision’s bedside emu™ brain scanner device. It is a lighter and miniaturised physical embodiment with expanded antennas (28), designed to provide full brain coverage in a single scan. The device will now be the subject of a series of studies and developments including usability, reliability, software development, functionality and other tests intended to meet international regulatory requirements.

Breakthrough Point-of-care Neurodiagnostics


VALUE PROPOSITION

- Ultra-light weight (under 12kgs / 26lbs)
- Rapid stroke and stroke sub-type detection
- Non-ionising, non-invasive and cost effective
- Can be operated by any healthcare professional with training
- Telehealth integration



First responder device is not yet approved for sale by the regulatory authorities. The device is subject to ongoing development. Roadmap below is indicative only and subject to change.

UPCOMING MILESTONES



For personal use only

In addition, under the Company's Project Agreement with the Australian Stroke Alliance (ASA), which is funded by the Commonwealth of Australia's Medical Research Future Fund (MRFF), the "Ambulance Device Fabrication" milestone has been achieved. EMVision has submitted the required documentation to the ASA to trigger a further \$600,000 non-dilutive milestone payment.

Pre-hospital workflow example



There is significant commercial opportunity for pre-hospital brain scanning of medical emergencies, such as suspected stroke. The device intends to open the door to earlier triage, transfer or treatment decisions, at the point-of-care, which has potential for substantial positive impact on patient care and healthcare costs. It is estimated that there are in excess of 60,000 road and air ambulances in the United States alone.¹

Professor Geoffrey Donnan, co-Chair of the Australian Stroke Alliance, emphasised the importance of the identification of blood as a prerequisite for therapeutic decision making in acute stroke management. "Early results are encouraging and the lightweight nature of the EMV device are likely to make it useful in the prehospital stroke environment."

Professor Stephen Davis, co-Chair of the Australian Stroke Alliance, said "We are looking forward to the validation of the sensitivity and specificity for detection of blood in hyperacute stroke patients using the EMV device, against CT scanning, the current gold standard in stroke management. The weight of the device – about 10 kilograms – compares extremely favourably to a conventional mobile CT scanner of at least 500 kilograms."

Stroke Foundation CEO, Dr Lisa Murphy, commented "This is an exciting step forward in reducing the gap that exists between regional and metropolitan stroke care. Every Australian patient deserves access to fast treatment and quality stroke care, regardless of their postcode. Access to fast diagnosis and treatment of stroke can be the difference between life or death and recovering well or living with severe disability, so technology like this is critical in improving outcomes for survivors of stroke."

Zoe Schofield, National Stroke Project Manager for Aeromedical Retrieval, Royal Flying Doctor Service, commented "As a key partner of the Australian Stroke Alliance, the RFDS is thrilled about the potential impact of EMVision's portable brain scanner on stroke outcomes for rural and remote Australians. I am incredibly privileged to lead the implementation of this world-first technology in aeromedical retrieval across Australia. Together, we're unlocking new possibilities to save lives and improve health."

EMVision CEO & MD, Scott Kirkland, commented "The build of our First Responder proof of concept device is the culmination of years of close work with leaders in the pre-hospital sector, including the Australian Stroke Alliance and the Royal Flying Doctor Service, to ensure that we are designing and developing a scalable First Responder solution to broadly transform patient outcomes. This means creating a device that aims to be economically viable, clinically powerful and attractive for pre-hospital emergency medical services worldwide. Core to these requirements is an ultra-light scanner that can be carried in a backpack, is easy, quick and safe to use, can be operated by trained paramedics without requiring a radiographer, can integrate with telehealth solutions such as Zeus and can distinguish if a suspected ischaemic or haemorrhagic stroke has occurred."

Authorised for release by the Board of the Company.

[ENDS]

¹ NASEMSO - National EMS Assessment - 2020

For further information, media or investor enquiries, please contact:

Dejan Toracki
Head of Investor Relations
+61 409 340 641
dtoracki@emvision.com.au

Sling & Stone
Media and Communications
emvision@slingstone.com
02 8073 5390

Scott Kirkland
CEO and Managing Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited (ASX:EMV) is an innovative Australian medical device company developing a novel approach to looking inside the human body. Our product pipeline includes portable, non-invasive, affordable and safe neuroimaging devices.

Our vision is to help transform and improve the timely diagnosis and treatment of stroke and other time sensitive medical emergencies, at the point-of-care.

EMVision has offices in Sydney and Brisbane www.emvisionmedical.com

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Inherent risks of Investment in Medical Device development Companies

There are a number of inherent risks associated with the development of new medical device products to a marketable stage. The clinical trial process, which is often lengthy, is designed to assess the safety and efficacy of a device prior to commercialisation and there is no guarantee of achieving the outcomes necessary to generate a viable commercial product. Other risks include uncertainty of patent protection and proprietary rights, the obtaining of necessary regulatory authority approvals and the evolving competitive landscape. Companies such as EMVision are dependent on the success of their research and development projects, product development and on the ability to attract funding to support these activities. Investment in research and development and novel product development cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore investment in Companies specialising in such development must be regarded as speculative. EMVision recommends that professional investment advice be sought prior to such investments and cautions investors that the risks of an investment in an entity such as EMVision is not limited to the risks disclosed in this announcement.